Search - tctmd.com

Displaying 1 - 20 of 151

Sort: Relevancy | Date

iFR-Guided Immediate PCI Not Superior to Deferred CMR-Guided Strategy in STEMI

News Conference News TCT 2025

iFR-Guided Immediate PCI Not Superior to Deferred CMR-Guided Strategy in STEMI

Yael L. Maxwell

October 28, 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Presentation TCT 2025

Beyond the Pivotal Trial: Real-World Impact in Uncontrolled Hypertension

Presenter: Karl Fengler

October 27, 2025

TTVR Remains Safe, Effective in Presence of CIED Leads

News Conference News TCT 2025

TTVR Remains Safe, Effective in Presence of CIED Leads

October 25, 2025

Left Distal Radial Access Doesn’t Reduce Radiation for Operators: DOSE

News Conference News TCT 2025

Left Distal Radial Access Doesn’t Reduce Radiation for Operators: DOSE

October 25, 2025

What’s Going to Be Hot at TCT 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

Percutaneous Mechanical Aspiration Promising for Right-Heart Infective Endocarditis

News Conference News TCT 2024

Percutaneous Mechanical Aspiration Promising for Right-Heart Infective Endocarditis

November 08, 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

News Conference News TCT 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Yael L. Maxwell

November 05, 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

November 01, 2024

QFR No Match for FFR in Guiding Revascularizations: FAVOR III Europe

News Conference News TCT 2024

QFR No Match for FFR in Guiding Revascularizations: FAVOR III Europe

October 30, 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

News Conference News TCT 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Michael O'Riordan

October 30, 2024

ECLIPSE: Balloon Angioplasty as Good as Orbital Atherectomy in Calcified Lesions

News Conference News TCT 2024

ECLIPSE: Orbital Atherectomy No Better Than Balloon Angioplasty in Calcified Lesions

Yael L. Maxwell

October 29, 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

News Conference News TCT 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

October 28, 2024

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

News Conference News TCT 2024

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

Michael O'Riordan

October 28, 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

News Conference News TCT 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

October 28, 2024

What’s Going to Be Big at TCT 2024?

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

News Conference News TCT 2023

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

Yael L. Maxwell

November 02, 2023

‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement: TRISCEND II

News Conference News TCT 2023

‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement: TRISCEND II

Michael O'Riordan

October 26, 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.